JP2001522842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001522842A5 JP2001522842A5 JP2000520430A JP2000520430A JP2001522842A5 JP 2001522842 A5 JP2001522842 A5 JP 2001522842A5 JP 2000520430 A JP2000520430 A JP 2000520430A JP 2000520430 A JP2000520430 A JP 2000520430A JP 2001522842 A5 JP2001522842 A5 JP 2001522842A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heteroaryl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 49
- 229910052739 hydrogen Inorganic materials 0.000 description 49
- 239000001257 hydrogen Substances 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 28
- 150000002431 hydrogen Chemical class 0.000 description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 23
- 125000001072 heteroaryl group Chemical group 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 125000000753 cycloalkyl group Chemical group 0.000 description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 17
- 125000003710 aryl alkyl group Chemical group 0.000 description 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 16
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 14
- 239000011737 fluorine Substances 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- -1 cdk3 Proteins 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000011394 anticancer treatment Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 101150012716 CDK1 gene Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 0 CC1=NC(**)=C(*)*1 Chemical compound CC1=NC(**)=C(*)*1 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 101150090188 Cdk8 gene Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101150112625 SSN3 gene Proteins 0.000 description 1
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 101150059448 cdk7 gene Proteins 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JYWSISJKMHOMBG-UHFFFAOYSA-N n-[5-[(4,5-dimethyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC=C1SCC1=NC(C)=C(C)O1 JYWSISJKMHOMBG-UHFFFAOYSA-N 0.000 description 1
- DTHXQOFAEWKCPU-UHFFFAOYSA-N n-[5-[(4-ethyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide Chemical compound CCC1=COC(CSC=2SC(NC(C)=O)=NC=2)=N1 DTHXQOFAEWKCPU-UHFFFAOYSA-N 0.000 description 1
- NRCIGJZLDFFIDD-UHFFFAOYSA-N n-[5-[(5-ethyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide Chemical compound O1C(CC)=CN=C1CSC1=CN=C(NC(C)=O)S1 NRCIGJZLDFFIDD-UHFFFAOYSA-N 0.000 description 1
- VNAAESWDZCUTMH-UHFFFAOYSA-N n-[5-[(5-ethyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]benzamide Chemical compound O1C(CC)=CN=C1CSC(S1)=CN=C1NC(=O)C1=CC=CC=C1 VNAAESWDZCUTMH-UHFFFAOYSA-N 0.000 description 1
- IQNVXJUIQPYTHB-UHFFFAOYSA-N n-[5-[(5-ethyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound O1C(CC)=CN=C1CSC(S1)=CN=C1NS(=O)(=O)C1=CC=CC=C1 IQNVXJUIQPYTHB-UHFFFAOYSA-N 0.000 description 1
- WKTFFSVUCQARKP-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-2,2-dimethylpropanamide Chemical compound S1C(NC(=O)C(C)(C)C)=NC=C1SCC1=NC=C(C(C)(C)C)O1 WKTFFSVUCQARKP-UHFFFAOYSA-N 0.000 description 1
- GFXMFSCCEVADLF-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC=C1SCC1=NC=C(C(C)(C)C)O1 GFXMFSCCEVADLF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6519597P | 1997-11-12 | 1997-11-12 | |
| US60/065,195 | 1997-11-12 | ||
| PCT/US1998/023197 WO1999024416A1 (en) | 1997-11-12 | 1998-11-02 | Aminothiazole inhibitors of cyclin dependent kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001522842A JP2001522842A (ja) | 2001-11-20 |
| JP2001522842A5 true JP2001522842A5 (enExample) | 2006-01-05 |
| JP4344084B2 JP4344084B2 (ja) | 2009-10-14 |
Family
ID=22060972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000520430A Expired - Fee Related JP4344084B2 (ja) | 1997-11-12 | 1998-11-02 | サイクリン依存性キナーゼのアミノチアゾール系阻害剤 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6040321A (enExample) |
| EP (1) | EP1042307B1 (enExample) |
| JP (1) | JP4344084B2 (enExample) |
| KR (2) | KR20030036862A (enExample) |
| CN (1) | CN1160343C (enExample) |
| AR (1) | AR017182A1 (enExample) |
| AT (1) | ATE374771T1 (enExample) |
| AU (1) | AU730607B2 (enExample) |
| BR (1) | BR9814124A (enExample) |
| CA (1) | CA2309551C (enExample) |
| CO (1) | CO4990957A1 (enExample) |
| CY (1) | CY1107509T1 (enExample) |
| CZ (1) | CZ297907B6 (enExample) |
| DE (1) | DE69838515T2 (enExample) |
| DK (1) | DK1042307T3 (enExample) |
| EG (1) | EG24028A (enExample) |
| ES (1) | ES2296347T3 (enExample) |
| HU (1) | HUP0004559A3 (enExample) |
| ID (1) | ID23983A (enExample) |
| IL (1) | IL135589A (enExample) |
| MY (1) | MY120779A (enExample) |
| NO (1) | NO316773B1 (enExample) |
| NZ (1) | NZ503828A (enExample) |
| PE (1) | PE131699A1 (enExample) |
| PL (1) | PL204642B1 (enExample) |
| PT (1) | PT1042307E (enExample) |
| RU (1) | RU2211839C2 (enExample) |
| TR (1) | TR200001344T2 (enExample) |
| TW (1) | TW593292B (enExample) |
| UY (1) | UY25239A1 (enExample) |
| WO (1) | WO1999024416A1 (enExample) |
| ZA (1) | ZA9810332B (enExample) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
| WO2000035455A1 (en) * | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
| US20040171632A1 (en) * | 1998-12-22 | 2004-09-02 | Gowan Richard Carleton | Combination chemotherapy |
| DE69928568T2 (de) * | 1998-12-22 | 2006-07-27 | Warner-Lambert Co. Llc | Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor |
| KR20010112408A (ko) * | 1999-04-07 | 2001-12-20 | 모리타 다카카즈 | Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도 |
| EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| DE60024631T2 (de) * | 1999-07-26 | 2006-06-14 | Banyu Pharma Co Ltd | Biaryl-harnstoff-derivate |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) * | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| MY125768A (en) * | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| US6534531B2 (en) * | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
| WO2001095856A2 (en) * | 2000-06-15 | 2001-12-20 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
| HRP20030116A2 (en) * | 2000-07-26 | 2005-02-28 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases |
| HK1052354A1 (zh) * | 2000-08-09 | 2003-09-11 | Agouron Pharmaceuticals, Inc. | 吡唑-噻唑化合物，包括它们的药物组分，和他们在抑制细胞周期蛋白依赖性激酶用途的方法 |
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| HUP0303538A2 (hu) * | 2000-12-21 | 2005-02-28 | Bristol-Myers Squibb Co. | Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| EP1353668B1 (en) | 2001-01-25 | 2008-03-19 | Bristol-Myers Squibb Company | Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer |
| WO2002074042A2 (en) * | 2001-03-19 | 2002-09-26 | Novartis Ag | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| ATE315555T1 (de) | 2001-05-11 | 2006-02-15 | Pfizer Prod Inc | Thiazolderivate und ihre verwendung als cdk- inhibitoren |
| CA2446939C (en) * | 2001-05-16 | 2005-08-02 | Matthias Stein-Gerlach | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| PL367938A1 (en) * | 2001-07-19 | 2005-03-07 | Pharmacia Italia S.P.A. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| CZ2004287A3 (cs) * | 2001-08-31 | 2004-10-13 | Bristol@Myersásquibbácompany | Prostředky a způsoby pro léčení rakoviny |
| US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| NZ539164A (en) * | 2002-09-04 | 2006-04-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002572A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina. |
| MXPA05002573A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7205308B2 (en) * | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1694705A (zh) * | 2002-09-04 | 2005-11-09 | 先灵公司 | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 |
| US7161003B1 (en) * | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| HK1079788A1 (zh) * | 2002-10-03 | 2006-04-13 | Novartis Ag | 适用於治疗2型糖尿病的作为葡萄糖激酶活化剂的取代的(噻唑-2-基)-酰胺或磺胺 |
| EP1549638B1 (en) | 2002-10-03 | 2007-10-03 | F. Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
| PL374758A1 (en) * | 2002-10-24 | 2005-10-31 | Merck Patent Gmbh | Methylene urea derivatives |
| AU2003302084A1 (en) * | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| CA2533803A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| US6949895B2 (en) * | 2003-09-03 | 2005-09-27 | Axcelis Technologies, Inc. | Unipolar electrostatic quadrupole lens and switching methods for charged beam transport |
| US7256208B2 (en) * | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| PL1723128T3 (pl) | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy |
| WO2005072731A1 (en) * | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US20050182105A1 (en) * | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7696241B2 (en) * | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| KR20070084325A (ko) | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
| EP1845094A4 (en) * | 2005-01-04 | 2009-12-16 | Univ Kanazawa Nat Univ Corp | METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON THE INHIBITORY EFFECT OF GSK3 BETA |
| US20100105745A1 (en) * | 2005-01-04 | 2010-04-29 | Toshinari Minamoto | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| MX2008000255A (es) * | 2005-07-14 | 2008-04-02 | Novo Nordisk As | Activadores de urea glucocinasa. |
| US8017781B2 (en) * | 2005-11-15 | 2011-09-13 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US20080188524A1 (en) * | 2006-10-25 | 2008-08-07 | Martin Augustin | Methods of treating pain |
| EP2089411A4 (en) | 2006-12-04 | 2010-01-27 | Univ Illinois | COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH CUPREDOXINES AND CPG-RICH DNA |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| AU2011252974A1 (en) | 2010-05-12 | 2012-12-13 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2012061190A1 (en) * | 2010-11-01 | 2012-05-10 | Romark Laboratories L.C. | Alkylsulfinyl-substituted thiazolide compounds |
| CN103442737B (zh) | 2011-01-20 | 2017-03-29 | 得克萨斯系统大学董事会 | Mri标记、递送和提取系统及其制造方法和用途 |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2014075391A1 (zh) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物 |
| WO2014151953A1 (en) * | 2013-03-15 | 2014-09-25 | The California Institute For Biomedical Research | Compounds and methods for inducing chondrogenesis |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| JP7028766B2 (ja) * | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| CR20180482A (es) * | 2016-04-06 | 2019-04-09 | Innovative Molecules Gmbh | Derivados de aminotiazol útiles como agentes antivíricos |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| AR113344A1 (es) * | 2017-10-05 | 2020-04-22 | Innovative Molecules Gmbh | Enantiómeros de una serie de compuestos antivirales |
| JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
| WO2020005807A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN116568671A (zh) * | 2020-10-16 | 2023-08-08 | 分子医学研究中心责任有限公司 | 杂环Cullin-RING泛素连接酶化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1088049A (en) * | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
| NO831160L (no) * | 1982-04-08 | 1983-10-10 | Erba Farmitalia | Fremstilling av substituerte penem-derivater |
| JPS6339868A (ja) * | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
| DE4119756A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung |
| JPH0859669A (ja) * | 1994-06-13 | 1996-03-05 | Takeda Chem Ind Ltd | セフェム化合物、その製造法及び剤 |
| KR980700077A (ko) * | 1994-11-29 | 1998-03-30 | 나까토미 히로타카 | 2-아미노티아졸유도체 및 그 염류로 이루어진 항균제 또는 살균제(Antibacterial Prepartion or Bactericide comprising 2-Aminothiazole Derivative or Salt Thereof |
-
1998
- 1998-10-21 US US09/176,239 patent/US6040321A/en not_active Expired - Lifetime
- 1998-11-02 PT PT98956431T patent/PT1042307E/pt unknown
- 1998-11-02 IL IL13558998A patent/IL135589A/en not_active IP Right Cessation
- 1998-11-02 CA CA002309551A patent/CA2309551C/en not_active Expired - Fee Related
- 1998-11-02 ES ES98956431T patent/ES2296347T3/es not_active Expired - Lifetime
- 1998-11-02 BR BR9814124-4A patent/BR9814124A/pt not_active Application Discontinuation
- 1998-11-02 WO PCT/US1998/023197 patent/WO1999024416A1/en not_active Ceased
- 1998-11-02 HU HU0004559A patent/HUP0004559A3/hu unknown
- 1998-11-02 AU AU12955/99A patent/AU730607B2/en not_active Ceased
- 1998-11-02 KR KR10-2003-7004561A patent/KR20030036862A/ko not_active Ceased
- 1998-11-02 ID IDW20000894A patent/ID23983A/id unknown
- 1998-11-02 DK DK98956431T patent/DK1042307T3/da active
- 1998-11-02 CN CNB988110911A patent/CN1160343C/zh not_active Expired - Fee Related
- 1998-11-02 TR TR2000/01344T patent/TR200001344T2/xx unknown
- 1998-11-02 DE DE69838515T patent/DE69838515T2/de not_active Expired - Lifetime
- 1998-11-02 RU RU2000115305/04A patent/RU2211839C2/ru not_active IP Right Cessation
- 1998-11-02 AT AT98956431T patent/ATE374771T1/de active
- 1998-11-02 EP EP98956431A patent/EP1042307B1/en not_active Expired - Lifetime
- 1998-11-02 PL PL340540A patent/PL204642B1/pl not_active IP Right Cessation
- 1998-11-02 KR KR10-2000-7004995A patent/KR100454426B1/ko not_active Expired - Fee Related
- 1998-11-02 NZ NZ503828A patent/NZ503828A/xx active Application Revival
- 1998-11-02 CZ CZ20001744A patent/CZ297907B6/cs not_active IP Right Cessation
- 1998-11-02 JP JP2000520430A patent/JP4344084B2/ja not_active Expired - Fee Related
- 1998-11-09 TW TW087118625A patent/TW593292B/zh not_active IP Right Cessation
- 1998-11-09 UY UY25239A patent/UY25239A1/es not_active IP Right Cessation
- 1998-11-11 ZA ZA9810332A patent/ZA9810332B/xx unknown
- 1998-11-11 CO CO98066514A patent/CO4990957A1/es unknown
- 1998-11-12 PE PE1998001093A patent/PE131699A1/es not_active Application Discontinuation
- 1998-11-12 EG EG140698A patent/EG24028A/xx active
- 1998-11-12 AR ARP980105716A patent/AR017182A1/es unknown
- 1998-11-12 MY MYPI98005150A patent/MY120779A/en unknown
-
2000
- 2000-04-27 NO NO20002153A patent/NO316773B1/no not_active IP Right Cessation
-
2007
- 2007-12-27 CY CY20071101633T patent/CY1107509T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001522842A5 (enExample) | ||
| CA2671982C (en) | Methods of using mek inhibitors | |
| Krisl et al. | Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| JP5765634B2 (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| RU2000115305A (ru) | Аминотриазольные ингибиторы циклинзависимых киназ | |
| JP2013508373A (ja) | Ｔｏｌｌ様受容体の調節因子 | |
| KR20170017932A (ko) | Ｍｄｍ２ 억제제의 간헐적 투여 | |
| EP2817011B1 (en) | Treatment of cancer | |
| JP2016520622A5 (enExample) | ||
| JP2015500884A (ja) | 癌を治療するための低酸素活性化プロドラッグおよびｍＴＯＲ阻害剤 | |
| JP2010159271A (ja) | エポシロンを含有する組合せ剤およびその医薬上の使用 | |
| TW202214239A (zh) | 用於治療貧血之alk2抑制劑 | |
| KR20190068519A (ko) | PIKfyve 억제제를 포함하는 조성물 및 RANK 신호전달의 억제와 관련된 방법 | |
| EP2403339B1 (en) | Combination cancer therapy with an akt inhibitor and other anticancer agents | |
| JP2020533292A (ja) | コパンリシブの製剤 | |
| De | SPEC–Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies, 12-Month Access, eBook: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies | |
| Chu et al. | Basic and clinical pharmacology | |
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| JP7280286B2 (ja) | びまん性大細胞型ｂ細胞リンパ腫を治療するための５－フルオロ－４－（４－フルオロ－２－メトキシフェニル）－ｎ－｛４－［（ｓ－メチルスルホンイミドイル）メチル］ピリジン－２－イル｝ピリジン－２－アミンの使用 | |
| US20100087399A1 (en) | Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer | |
| US20160143914A1 (en) | Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof | |
| WO2016113187A1 (en) | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating leukemias | |
| AU2024233869A1 (en) | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy | |
| CN107428707A (zh) | 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基亚磺酰亚胺基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗多发性骨髓瘤的用途 |